专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2022235621A1 METHODS FOR TREATING A PULMONARY DISEASE WITH AN ALK-5 (TGF BETA R1) INHIBITOR 审中-公开
公开(公告)号：WO2022235621A1
公开(公告)日：2022-11-10
申请号：PCT/US2022/027402
申请日：2022-05-03
申请人： THIRONA BIO, INC.
发明人： BULLOUGH, David, A. , FOULKES, John, Gordon , BEELEY, Nigel, R.a. , CRYSTAL, Roger
IPC分类号： A61K31/5377 , A61K9/00 , A61K31/444 , A61K31/4709
摘要： The present invention concerns liquid, dry powder and metered-dose formulations for therapeutic inhaled delivery of ALK5 (TGF-βR1) inhibitor containing compositions to desired anatomical sites, for treatment or prophylaxis of a variety of pulmonary disease conditions such as Idiopathic Pulmonary Fibrosis, Idiopathic Interstitial Pneumonia, scleroderma-associated interstitial lung disease, sarcoidosis, cystic fibrosis, lung cancer, and a COVID infection.

2. 发明申请

WO2018183538A1 3'-O-MODIFIED NUCLEOTIDE ANALOGUES WITH DIFFERENT CLEAVABLE LINKERS FOR ATTACHING FLUORESCENT LABELS TO THE BASE FOR DNA SEQUENCING BY SYNTHESIS 审中-公开
公开(公告)号：WO2018183538A1
公开(公告)日：2018-10-04
申请号：PCT/US2018/024895
申请日：2018-03-28
申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK , JU, Jingyue , LI, Xiaoxu , CHEN, Xin , KUMAR, Shiv , RUSSO, James , CHIEN, Minchen
发明人： JU, Jingyue , LI, Xiaoxu , CHEN, Xin , KUMAR, Shiv , RUSSO, James , CHIEN, Minchen
IPC分类号： A61K31/7052 , C07C323/60 , C07D207/40 , C07D207/46
摘要： Disclosed herein, inter alia, are nucleotide analogues, and methods of use thereof, having cleavable orthogonal linkers.

3. 发明申请

WO2018039475A8 USE OF PRIDOPIDINE FOR TREATING DYSTONIAS 审中-公开
公开(公告)号：WO2018039475A8
公开(公告)日：2018-03-01
申请号：PCT/US2017/048458
申请日：2017-08-24
申请人： TEVA PHARMACEUTICALS INTERNATIONAL GMBH , HAYDEN, Michael , PAPAPETROPOULOS, Spyridon , SAVOLA, Juha-MATTI , EYAL, Eli , BOROWSKY, Beth , GRACHEV, Igor, D. , GORDON, Mark, Forrest
发明人： HAYDEN, Michael , PAPAPETROPOULOS, Spyridon , SAVOLA, Juha-MATTI , EYAL, Eli , BOROWSKY, Beth , GRACHEV, Igor, D. , GORDON, Mark, Forrest
IPC分类号： A61K31/451
摘要： The invention provides a method of treating a subject afflicted with a dystonia, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.

4. 发明申请

WO2017218697A1 IDENTIFICATION OF COMPOUNDS THAT TARGET THE RNA-BINDING PROTEIN TIA-1 AN IMPORTANT REGULATOR OF STRESS VULNERABILITY IN BOTH MICE AND HUMANS 审中-公开
标题翻译：靶向RNA结合蛋白TIA-1成为小鼠和人类应激易感性重要调节因子的化合物的鉴定
公开(公告)号：WO2017218697A1
公开(公告)日：2017-12-21
申请号：PCT/US2017/037544
申请日：2017-06-14
申请人： THE TRUSTEES COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
发明人： RAYMAN, Joseph, B. , KANDEL, Eric, R.
IPC分类号： A61K38/17 , C07K14/435 , C07K14/47 , G01N33/68
CPC分类号： C07K14/47 , A61K31/375 , A61K31/5365 , A61K31/65 , C07K14/435 , G01N33/542
摘要： This invention provides a method of ameliorating the symptoms of, or treating post-traumatic stress disorder in a mammal, the method comprising administering to the mammal an effective amount of a compound that upregulates TIA-1 multimerization. This invention also provides a method of ameliorating the symptoms of, or treating post-traumatic stress disorder in a mammal, the method comprising administering to the mammal an effective amount of a compound that inhibits TIA-1 multimerization. This invention also provides a method for determining whether a predetermined compound upregulates or inhibits TIA-1 multimerization, using fluoresence resonance energy transfer (FRET), the method comprising: expressing recombinant TIA-CFP and TIA-YFP; exposing the recombinant TIA-CFP and TIA-YFP to such predetermined compound; exciting the TIA-CFP with a laser; and measuring the fluorescence of TIA-YFP, wherein an increase in fluorescence relative to TIA-CFP and TIA-YFP not exposed to the predetermined compound indicates that the predetermined compound upregulates TIA-1 multimerization and a decrease in fluorescence relative to TIA-CFP and TIA-YFP not exposed to the predetermined compound indicates that the predetermined compound inhibits TIA-1 multimerization.
摘要翻译：本发明提供了改善哺乳动物的症状或治疗创伤后应激障碍的方法，所述方法包括给哺乳动物施用有效量的上调TIA-1多聚化作用的化合物。本发明还提供了改善哺乳动物的症状或治疗创伤后应激障碍的方法，该方法包括给哺乳动物施用有效量的抑制TIA-1多聚化作用的化合物。本发明还提供了使用荧光共振能量转移（FRET）确定预定化合物是否上调或抑制TIA-1多聚化的方法，所述方法包括：表达重组TIA-CFP和TIA-YFP; 将重组TIA-CFP和TIA-YFP暴露于这种预定化合物; 用激光激发TIA-CFP; 并测量TIA-YFP的荧光，其中相对于未暴露于预定化合物的TIA-CFP和TIA-YFP的荧光增加表明预定化合物相对于TIA-CFP上调TIA-1多聚化和荧光下降，并且未暴露于预定化合物的TIA-YFP表明预定化合物抑制TIA-1多聚化。

5. 发明申请

WO2017177021A1 METHOD OF TREATING EARLY STAGE DUPUYTREN'S DISEASE 审中-公开
标题翻译：治疗早期DUPUYTREN'S疾病的方法
公开(公告)号：WO2017177021A1
公开(公告)日：2017-10-12
申请号：PCT/US2017/026382
申请日：2017-04-06
申请人： 180 THERAPEUTICS LP
发明人： NANCHAHAL, Jagdeep , LARSEN, Glenn R. , FELDMANN, Marc
IPC分类号： A61K39/395 , A61K39/44 , A61K49/16
摘要： The subject invention provides a method of treating an individual afflicted with early stage Dupuytren' s disease characterized by the presence of one or more nodules on the individual's hand which comprises injecting into each nodule a pharmaceutical composition comprising an amount of an antihuman TNFa antibody or fragment thereof effective to treat the individual, wherein the pharmaceutical composition is in the form of a liquid and between 0.1 ml and 0.6 ml of the composition is injected into each nodule. This invention also provides for a pre-filled syringe for carrying out the above-described method.
摘要翻译：本发明提供了治疗患有早期Dupuytren病的个体的方法，其特征在于个体手上存在一个或多个结节，该方法包括向每个结节中注射药物组合物，所述药物组合物包含有效治疗个体的抗人TNFα抗体或其片段的量，其中所述药物组合物呈液体形式并且将0.1ml至0.6ml的组合物注射到每个结节中。本发明还提供了用于执行上述方法的预填充注射器。

6. 发明申请

WO2017048457A1 COMBINATION OF LAQUINIMOD AND PRIDOPIDINE TO TREAT MULTIPLE SCLEROSIS 审中-公开
标题翻译： LAQUINIMOD和PRIDOPIDINE治疗多发性硬化症的联合
公开(公告)号：WO2017048457A1
公开(公告)日：2017-03-23
申请号：PCT/US2016/047788
申请日：2016-08-19
申请人： TEVA PHARMACEUTICALS INDUSTRIES LTD. , TEVA PHARMACEUTICALS USA, INC. , GEVA, Michal , KAYE, Joel
发明人： GEVA, Michal , KAYE, Joel
IPC分类号： A61K31/451 , A61K31/4704
CPC分类号： A61K31/451 , A61K31/4704 , A61K2300/00
摘要： This invention provides a method of treating a subject afflicted with multiple sclerosis (MS) or presenting a clinically isolated syndrome (CIS) comprising administering to the subject laquinimod as an add-on to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising laquinimod and pridopidine for treating a subject afflicted with MS or presenting CIS. This invention also provides laquinimod for use as an add-on therapy or in combination with pridopidine in treating a subject afflicted with MS or presenting CIS. This invention further provides use of laquinimod and pridopidine in the preparation of a combination for treating a subject afflicted with MS or presenting CIS.
摘要翻译：本发明提供了治疗患有多发性硬化症（MS）或呈现临床分离综合征（CIS）的受试者的方法，其包括向所述受试者的拉喹莫德作为与所述阿维肽的附加物或与其结合施用。本发明还提供一种包含药物组合物和药物组合物，其包含用于治疗患有MS或显示CIS的受试者的拉喹莫德和格列方啶。本发明还提供了用作附加疗法的拉喹莫德或与治疗患有MS或呈现CIS的受试者的格列吡啶的组合。本发明进一步提供了用于治疗患有MS或呈现CIS的受试者的组合的拉喹莫德和派多定的用途。

7. 发明申请

WO2016209596A1 12H-BENZO[B]XANTHEN-12-ONES, COMPOSITIONS CONTAINING, AND USES OF, SAME 审中-公开
标题翻译： 12H-BENZO [B] XANTHEN-12-ONES，组合物及其用途
公开(公告)号：WO2016209596A1
公开(公告)日：2016-12-29
申请号：PCT/US2016/035978
申请日：2016-06-06
申请人： THESAN PHARMACEUTICALS, INC. , BEELEY, Nigel Robert Arnold , WELGUS, Howard Glenn , BIRNBAUM, Jay Edward , FOULKES, J. Gordon , JENKINSON, Celia Patricia , SAURAT, Jean Hilaire
发明人： BEELEY, Nigel Robert Arnold , WELGUS, Howard Glenn , BIRNBAUM, Jay Edward , FOULKES, J. Gordon , JENKINSON, Celia Patricia , SAURAT, Jean Hilaire
IPC分类号： A61K47/14 , A61K47/06 , A61K31/5575
CPC分类号： C07D311/78 , A61K9/0014 , A61K31/352 , A61K31/357 , A61K31/366 , A61K48/00 , A61P17/08 , C07B2200/07 , C07B2200/09 , C07D493/04 , C07D493/14
摘要： The present invention provides compounds of structure (I), methods of using such compounds, and pharmaceutical compositions containing such compounds. In addition, this invention provides methods for the treatment and/or prevention of disease states mediated by Aryl Hydrocarbon receptor pathways.
摘要翻译：本发明提供结构（I）的化合物，使用这些化合物的方法和含有这些化合物的药物组合物。此外，本发明提供了治疗和/或预防由芳基烃受体途径介导的疾病状态的方法。

8. 发明申请

WO2016172124A1 SELECT SINGLE NUCLEOTIDE POLYMORPHISMS PREDICTIVE OF RESPONSE TO GLATIRAMER ACETATE 审中-公开
标题翻译：选择单核苷酸多态性对乙酰胆碱反应的预测
公开(公告)号：WO2016172124A1
公开(公告)日：2016-10-27
申请号：PCT/US2016/028316
申请日：2016-04-19
申请人： TEVA PHARMACEUTICAL INDUSTRIES LTD. , GROSSMAN, Iris , HAYDEN, Michael , ROSS, Colin, James Douglas , LAIFENFELD, Daphna , DAVIS, Matthew
发明人： GROSSMAN, Iris , HAYDEN, Michael , ROSS, Colin, James Douglas , LAIFENFELD, Daphna , DAVIS, Matthew
IPC分类号： A61K38/02 , C12Q1/68
CPC分类号： C12Q1/6883 , A61K9/0019 , A61K38/02 , A61K45/06 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156
摘要： The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent, with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: (i) determining a genotype of the subject at a location corresponding to the location of one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of: rs1894408, kgp7747883, kgp6599438, rs10162089, rs16886004, kgp8110667, kgp8817856, kgp24415534, kgp6214351 and rs759458, (ii) identifying the subject as a predicted responder to glatiramer acetate if the genotype of the subject contains one or more A alleles at the location of kgp8110667, rs10162089, rs759458 and kgp6214351, or one or more G alleles at the location of kgp24415534, kgp6599438, kgp7747883, kgp8817856, rs16886004 and rs1894408; and iii) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.
摘要翻译：本发明提供了一种用多种硬化症或单一临床攻击治疗患有多发性硬化的人类受试者的方法，所述多发性硬化症包括含有醋酸格拉默和药学上可接受的载体的药物组合物，包括以下步骤：（i）确定对应于选自以下的一个或多个单核苷酸多态性（SNP）的位置的对象：rs1894408，kgp7747883，kgp6599438，rs10162089，rs16886004，kgp8110667，kgp8817856，kgp24415534，kgp6214351和rs759458，（ii）鉴定该受试者作为乙酸格拉默的预测应答者，如果受试者的基因型在kgp8110667，rs10162089，rs759458和kgp6214351的位置包含一个或多个A等位基因，或位于kgp24415534，kgp6599438，kgp7747883，kgp8817856的一个或多个G等位基因，rs16886004和rs1894408; 以及iii）仅当所述受试者被鉴定为乙酸格拉默的预测应答者时，向受试者施用包含乙酸格拉默和药学上可接受的载体的药物组合物。

9. 发明申请

WO2016134257A8 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DEPRESSIVE AND STRESS DISORDERS 审中-公开
公开(公告)号：WO2016134257A8
公开(公告)日：2016-08-25
申请号：PCT/US2016/018679
申请日：2016-02-19
申请人： LIXTE BIOTECHNOLOGY, INC. , KOVACH, John, S. , LECCA, Salvatore , MAMELI, Manuel , INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
发明人： KOVACH, John, S. , LECCA, Salvatore , MAMELI, Manuel
IPC分类号： A61K31/336 , C07D303/32
摘要： A method of treating a depressive or stress disorder in a subject afflicted therewith comprising administering to the subject an effective amount of a compound having the structure: (I).

10. 发明申请

WO2016130814A1 INHIBITORS OF INDUCED MMP-1 PRODUCTION 审中-公开
标题翻译：诱导MMP-1生产的抑制剂
公开(公告)号：WO2016130814A1
公开(公告)日：2016-08-18
申请号：PCT/US2016/017562
申请日：2016-02-11
申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK , D'ARMIENTO, Jeanine , SHIOMI, Takayuki
发明人： D'ARMIENTO, Jeanine , SHIOMI, Takayuki
IPC分类号： A61K45/06
CPC分类号： A61K31/366 , A61K9/0014 , A61K9/0073 , A61K31/135 , A61K31/138 , A61K31/381 , A61K31/397 , A61K31/405 , A61K31/4418 , A61K31/47 , A61K31/496 , G01N33/5008 , G01N33/6893 , G01N2333/96494
摘要： The present invention provides methods and compositions of prophylaxis for, or for treating, chronic obstructive pulmonary disease (COPD), cancer, arthritis, skin damage, or atherosclerotic plaque rupture in a subject in need thereof, which comprise i) a statin or ii) a selective serotonin reuptake inhibitor (SSRI).
摘要翻译：本发明提供预防或治疗有需要的受试者的慢性阻塞性肺病（COPD），癌症，关节炎，皮肤损伤或动脉粥样硬化斑块破裂的方法和组合物，其包括i）他汀类或ii）选择性5-羟色胺再摄取抑制剂（SSRI）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式